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The recent licensing of talimogene laherparepvec 
(Imlygic™) for treatment of malignant melanoma by the 
FDA and EMA provides proof of the long heralded clinical 
potential of oncolytic viruses (OV) [1]. Some three 
decades on from their first clinical evaluation, mounting 
evidence suggests that OV may be ready to deliver on 
their promise as powerful immunostimulatory anti-cancer 
agents.
The use of virotherapies offers unique advantages 
compared to conventional drug- or antibody-based anti-
cancer agents. A major advantage lies in the capacity of 
virotherapies to self-amplify following infection of cancer 
cells – a feature unique to biological agents. Infected cells 
produce tens of thousands of daughter virions, before 
lysing the infected cell, spreading virions to surrounding 
cells, repeating and amplifying the process. The lytic 
nature of OV-induced cell death is highly immunogenic. It 
induces a robust anti-tumor immune response, which can 
be further exacerbated through the in situ, virus-mediated 
over-expression of engineered immunostimulatory 
transgenes. Virotherapies thus have the potential to turn 
immunologically “cold” tumors “hot”, with increasing 
evidence suggesting resistant tumors can be sensitized to 
subsequent immunotherapies through pre-treatment with 
OV, which results in significant tumor regression [2, 3].
Unfortunately, viruses – including those based on 
the well-studied oncolytic vector, adenovirus serotype 
5 (Ad5) – have not evolved to be intrinsically tumor-
selective. Rather, they have evolved sophisticated means 
to infect healthy cells, efficiently delivering their DNA 
payload to the nucleus. As such, the selectivity of OV 
for cancer cell killing most commonly relies upon subtle 
changes or reassortments of viral early genes to allow 
preferential replication within transformed cells, with 
minimal replication in non-transformed cells [4, 5]. Using 
this approach, the pool of vector available for transducing 
transformed cells is depleted by uptake in “off-target” 
organs, with consequent dose limiting toxicities. Clearly, 
the therapeutic index of virotherapies, especially those 
introduced via the intravenous route, could be improved 
through a systemic and rational redesign of the viral 
capsid to preclude native means of infection. For Ad5, 
interactions leading to vector sequestration are relatively 
well defined. Cell entry is initiated by interaction between 
the extended fiber knob protein to the primary receptor, 
Coxsackie and Adenovirus Receptor (CAR) [6]. Following 
attachment, cellular internalization is stimulated by 
secondary interactions between the penton base and 
cellular αvβ3/5 integrins, resulting in uptake via clathrin-
coated endosomes [7]. For cancer therapies, CAR and 
αvβ3/5 integrins represent poor targets for therapeutic 
delivery of biologics. CAR is expressed in most organs, 
but is anatomically restricted to tight junctions [8], 
whilst loss of CAR expression with tumor progression 
has been previously reported [9, 10]. The expression of 
CAR on human erythrocytes may also act as a “sink” for 
circulating Ad5, trapping virions within the bloodstream. 
Furthermore, binding of the Ad5 virion to the co-receptor 
αvβ3/5 has been reported to result in sequestration by 
splenic macrophages, degrading virions and inducing 
a potent innate antiviral response, with consequent 
dose-limiting toxicities [11, 12]. Of critical relevance 
for targeting metastases is the high affinity interaction 
between the Ad5 major coat protein, hexon, and 
circulating coagulation zymogen, FX. This high-affinity 
interaction results in rapid, selective and efficient uptake 
of Ad5 by hepatocytes via heparan sulphate proteoglycans 
(HSPG) [13-15]. In summary, each of the major Ad5 
capsid proteins – hexon, penton base and fiber – plays a 
major role in “off-target” uptake of Ad5, inducing dose-
limiting toxicities whilst rapidly and efficiently depleting 
the pool of vector available for therapeutic delivery to the 
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Figure 1: Refinement of Ad5 into a highly tumor-
selective virotherapy. Successful intravascular tumor-
targeting of Ad5 is limited by interactions involving each of the 
major capsid proteins, resulting in “off-target” sequestration, 
predominantly in the liver and spleen. To overcome these 
limitations, the Ad5
NULL
 oncolytic virus harbours mutations 
in each of the major capsid proteins – hexon, penton base and 
fiber – to preclude uptake via all described native routes. To 
efficiently target the Ad5
NULL
 platform vector to transformed 
epithelial cells expressing αvβ6 integrin, the vector contains an 
additional 20-amino-acid (A20) peptide sequence. The resultant 
virotherapy, Ad5
NULL
-A20, selectively and efficiently infects 
aggressively transformed cells via αvβ6 integrin.
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tumor (Figure 1).
To generate a refined, tumor-selective Ad5 
virotherapy, Uusi-Kerttula et al recently reported the 
construction of an oncolytic vector harboring modifications 
in each of the major capsid proteins to preclude all native 
routes of infection [16]. The resultant, triply modified 
platform vector Ad5
NULL
 is defective in uptake and thus 
cannot be produced without additional modifications to 
empower the vector with a new means of cellular entry, 
together with a surrogate rescue cell line for propagation. 
To address this, the authors engineered αvβ6 tropism 
into the vector, through incorporation of a 20-amino-
acid αvβ6 peptide ligand, A20, into the Ad5 fiber knob. 
αvβ6 is a compelling candidate for tumor targeting: it is 
undetectable in healthy epithelial cells, but over-expressed 
in a range of aggressively transformed cancers, where it is 
involved in TGF-β signaling, invasion and metastasis [17], 
and where over-expression correlates with poor patient 
prognosis [18]. The resultant vector, Ad5
NULL
-A20, was 
rescued in 293-β6 cells, and evaluated further. In vitro, the 
authors demonstrated Ad5
NULL
-A20 was devoid of native 
means of cellular infection, and infected cells entirely 
in an αvβ6-dependent fashion. Experiments performed 
in the presence of neutralizing serum demonstrated that 
the virotherapy appeared capable of at least partially 




abolished “off-target” uptake via the liver and spleen, 
including a remarkable 7-log reduction in vector genomes 
recovered from the liver. In a ovarian cancer xenograft 
model, Ad5
NULL
-A20 vector could be visualized infecting 
tumor cells selectively and efficiently in animals with 
peritoneal tumors. The treatment resulted in complete 
survival in the Ad5
NULL
-A20 cohort after >100 days, as 
opposed to a median survival time of ~55 days for mice 
treated with unrefined OV, and ~45 days for untreated 
mice. This efficacy study also highlighted the absolute 
requirement for the combination of both de-targeting and 
re-targeting for effective treatment, since mice treated 
with Ad5-A20 (containing the αvβ6 re-targeting peptide 
insert but no de-targeting modifications) failed to improve 
survival over unrefined Ad5.
The production and characterization of the Ad5
NULL
 
platform and efficient retargeting to αvβ6 integrin via 
A20 peptide represents a milestone in the development 
of fully refined virotherapies for personalized cancer 
treatment. Whilst the anti-cancer activity addressed 
to date has focused solely on oncolytic potential of 
the vector, additional refinement to express relevant 
immunomodulatory transgenes is certain to further 
enhance anticancer effects. It remains to be seen whether 
the Ad5
NULL
 platform can be adapted to tailor virotherapies 
towards other tumor-restricted receptors. Assuming this 
will be possible, this technology advances us towards an 
era where the development of precision virotherapies for 
individualized patient treatment may well become reality 
[19].
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